• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Heart J Acute Cardiovasc Care . The peak levels of highly sensitive troponin I predicts in-hospital mortality in COVID-19 patients with cardiac

tetano

Editor, Senior Moderator
Eur Heart J Acute Cardiovasc Care


. 2020 Oct 28;zuaa019.
doi: 10.1093/ehjacc/zuaa019. Online ahead of print.
The peak levels of highly sensitive troponin I predicts in-hospital mortality in COVID-19 patients with cardiac injury: a retrospective study


Yaxin Wang[SUP] 1 [/SUP], Huaqing Shu[SUP] 1 [/SUP], Hong Liu[SUP] 1 [/SUP], Xia Li[SUP] 2 [/SUP], Xing Zhou[SUP] 2 [/SUP], Xiaojing Zou[SUP] 1 [/SUP], Shangwen Pan[SUP] 1 [/SUP], Jiqian Xu[SUP] 1 [/SUP], Dan Xu[SUP] 1 [/SUP], Xin Zhao[SUP] 1 [/SUP], Xiaobo Yang[SUP] 1 [/SUP], Yuan Yu[SUP] 1 [/SUP], Yin Yuan[SUP] 1 [/SUP], Hong Qi[SUP] 1 [/SUP], Qiongya Wang[SUP] 2 [/SUP], You Shang[SUP] 1 [/SUP]



Affiliations

Abstract

Aims: To investigate the association between levels of highly sensitive troponin I (hs-troponin I) and mortality in novel coronavirus disease 2019 (COVID-19) patients with cardiac injury.
Methods and results: We retrospectively reviewed the medical records of all COVID-19 patients with increased levels of hs-troponin I from two hospitals in Wuhan, China. Demographic information, laboratory test results, cardiac ultrasonographic findings, and electrocardiograms were collected, and their predictive value on in-hospital mortality was explored using multivariable logistic regression. Of 1500 patients screened, 242 COVID-19 patients were enrolled in our study. Their median age was 68 years, and (48.8%) had underlying cardiovascular diseases. One hundred and seventy-six (72.7%) patients died during hospitalization. Multivariable logistic regression showed that C-reactive protein (>75.5 mg/L), D-dimer (>1.5 μg/mL), and acute respiratory distress syndrome were risk factors of mortality, and the peak hs-troponin I levels (>259.4 pg/mL) instead of the hs-troponin I levels at admission was predictor of death. The area under the receiver operating characteristic curve of the peak levels of hs-troponin I for predicting in-hospital mortality was 0.79 (95% confidence interval, 0.73-0.86; sensitivity, 0.80; specificity, 0.72; P < 0.0001).
Conclusion: Our results demonstrated that the risk of in-hospital death among COVID-19 patients with cardiac injury can be predicted by the peak levels of hs-troponin I during hospitalization and was significantly associated with oxygen supply-demand mismatch, inflammation, and coagulation.

Keywords: COVID-19; Cardiac injury; Levels of troponin I at admission; Mortality; Peak levels of troponin I.
 
Back
Top Bottom